alexa Cardiomyocyte Apoptosis Versus Autophagy With Prolonged Doxorubicin Treatment: Comparison With Osteosarcoma Cells
ISSN: 2161-0533

Orthopedic & Muscular System: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Orthopedics & Rheumatology
July 28-30, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Crispin R Dass
ScientificTracks Abstracts: Orthop Muscul Syst
DOI: 10.4172/2161-0533.S1.016
D oxorubicin (Dox), a frontline chemotherapeutic against osteosarcoma (OS), is plagued by cardiotoxicity amongst other side-effects. Our lab examined apoptotic (Bax) and autophagic (Beclin-1) biomarker levels in human osteosarcoma and cardiomyocyte cell lines as well as in various tissues when mice were exposed to low (1 mg/kg, thrice weekly) and high (3 mg/ kg thrice weekly) dose Dox for a month. There was a decrease in Bax and increase in Beclin-1 in cardiac tissue in the high dose group. At low Dox doses of 10 and 100 nM in cardiomyocytes and OS cells, there was a pro-apoptotic effect, with a quicker response in the 100 nM condition, and a slower but steady increase of a pro-apoptotic response at the lower 10 nM dose. However, electron microscopy (EM) revealed changes to human OS cells that resembled autophagy. In culture, cells of both cardiomyocytes and OS revealed a predominant proapoptotic response at the expense of autophagy, though autophagy may be occurring as EM demonstrated
Crispin R Dass obtained his B App. Sci. (Hons) and PhD from Charles Sturt University, Australia. He has 22 years of basic and applied research in cancer. He has worked on bigpharma projects (Amgen, Novartis, Glaxo-Wellcome, Johnson & Johnson). He has published in Nature Medicine, Journal of the National Cancer Institute, Journal of Controlled Release and Biomaterials. He has published 147 papers to date, 165 conference presentations, an h-index of 33, with total number of citations for his papers at ~3400. He has also reviewed original research papers in New England Journal of Medicine and Lancet and Nature Communications
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version